Effects of intravenous administration of clarithromycin on plasma levels of gastrin and group I pepsinogen

Erythromycin and some of its derivatives have prokinetic gastrointestinal properties. In addition, erythromycin has been shown to stimulate isolated chief cells of the gastric mucosa, and to activate pepsin secretion. The above study was aimed at ascertaining in a group of dyspeptic patients whether...

Full description

Saved in:
Bibliographic Details
Published inClinica terapeutica Vol. 145; no. 10; p. 277
Main Authors Pustorino, S, Turiano, S, Pizzimenti, C, Calipari, G, Federico, G, D'Amico, G, Sinopoli, C, Martinez, P, Guerrisi, O, Luzza, G
Format Journal Article
LanguageItalian
Published Italy 01.10.1994
Subjects
Adult
Aged
Clarithromycin - administration & dosage
Clarithromycin - pharmacology
Dyspepsia - blood
Female
Gastrins - blood
Humans
Infusions, Intravenous
Male
Middle Aged
Pepsinogens - blood
Online AccessGet more information

Cover

More Information
Summary:Erythromycin and some of its derivatives have prokinetic gastrointestinal properties. In addition, erythromycin has been shown to stimulate isolated chief cells of the gastric mucosa, and to activate pepsin secretion. The above study was aimed at ascertaining in a group of dyspeptic patients whether clarithromycin, a structural analogue of erythromycin, is apt to modify certain functional parameters of gastric secretion, above all the patterns of gastrin and PG-I secretion. A 20-minute intravenous clarithromycin infusion (1.5 mg/kg) in fasting subjects has brought about a significant reduction (at 20 and 45 minutes from the start of infusion) of circulating gastrin (about 23%) and, after a meal, a 69% increase. No change of plasma PG-I level was observed either after placebo or after the active substance. These findings suggest that in vivo and at the doses used in our experiment clarithromycin has no influence on plasma PG-I release and is apt to modify the fasting and postprandial gastrin releasing pattern.
ISSN:0009-9074